Related Experiment Videos
Celecoxib in human milk: a case report
David C Knoppert1, Diana Stempak, Sylvain Baruchel
1Department of Pharmacy, St Joseph's Hospital, Department of Paediatrics, University of Western Ontario, London, Ontario, Canada. dave.knoppert@sjhc.london.on.ca
Pharmacotherapy
|January 14, 2003
Summary
This study examined celecoxib transfer into breast milk. Celecoxib was detected in breast milk, with an elimination half-life of 4.0-6.5 hours, informing infant safety.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Lactation Studies
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) like celecoxib are frequently used by women of reproductive age.
- Limited data exist on celecoxib transfer into human breast milk and its safety for nursing infants.
Observation:
- A case study involved a breastfeeding mother who received oral celecoxib (100 mg) post-surgery.
- Breast milk samples were collected and analyzed to determine celecoxib concentration and elimination.
- The mother temporarily withheld breastfeeding for 48 hours after the last celecoxib dose.
Findings:
- Celecoxib was detected in breast milk, with a peak concentration of 133 ng/ml approximately 5 hours after a 100-mg dose.
- The elimination half-life of celecoxib in breast milk was determined to be between 4.0 and 6.5 hours.
Implications:
- This preliminary data provides crucial information for counseling breastfeeding mothers regarding celecoxib use.
- Further research is needed to substantiate and expand upon these findings for comprehensive infant safety assessments.
- Understanding celecoxib's pharmacokinetic profile in breast milk aids in clinical decision-making for lactating women.